Enhanced pulmonary toxicity in smokers with germ-cell cancer treated with Cis-platinum, vinblastine and bleomycin: A long-term follow-up

Imatinib may reduce chemotherapy-induced pneumonitis. A report on four cases from the SWENOTECA

“…But these reductions in capacity are mostly reversible during follow-up. In the majority of previous studies, both decreased VC and FVC observed during chemotherapy are usually normalized at follow-up [21][22][23][24]. However, the increased mortality as a result of respiratory diseases among chemotherapy-treated testicular cancer survivors is worrisome [1].…”

Imatinib may reduce chemotherapy-induced pneumonitis. A report on four cases from the SWENOTECA

“…But these reductions in capacity are mostly reversible during follow-up. In the majority of previous studies, both decreased VC and FVC observed during chemotherapy are usually normalized at follow-up [21][22][23][24]. However, the increased mortality as a result of respiratory diseases among chemotherapy-treated testicular cancer survivors is worrisome [1].…”

A case of bleomycin-induced lung toxicity

“…Lung toxicity occurs sporadically at doses less than 450 IU but at doses above this range the incidence rises steeply [5,6]. Smoking is another risk factor for bleomycininduced pulmonary toxicity [14]. Other suggested risk factors include dose rate, combination with other drugs, e.g.…”

Life-Threatening Pneumonitis Related to Docetaxel Chemotherapy

“…Drug interactions with other concomitant drugs or treatments may increase the risk of pulmonary toxicity, as with docetaxel and gemcitabine 13 , or concomitant radiotherapy 14 . Renal dysfunction may increase risk of pulmonary toxicity, as noted with bleomycin 17,18 , whilst prior smoking history may also increase risk of bleomycin related pulmonary toxicity 19,20 . The exact mechanisms by which cytotoxic agents cause lung injury have not been completely elucidated, however two main mechanisms are recognised 21 .…”

Imatinib may reduce chemotherapy-induced pneumonitis. A report on four cases from the SWENOTECA

“…But these reductions in capacity are mostly reversible during follow-up. In the majority of previous studies, both decreased VC and FVC observed during chemotherapy are usually normalized at follow-up [21][22][23][24]. However, the increased mortality as a result of respiratory diseases among chemotherapy-treated testicular cancer survivors is worrisome [1].…”

A case of bleomycin-induced lung toxicity

“…Lung toxicity occurs sporadically at doses less than 450 IU but at doses above this range the incidence rises steeply [5,6]. Smoking is another risk factor for bleomycininduced pulmonary toxicity [14]. Other suggested risk factors include dose rate, combination with other drugs, e.g.…”

Life-Threatening Pneumonitis Related to Docetaxel Chemotherapy

“…Drug interactions with other concomitant drugs or treatments may increase the risk of pulmonary toxicity, as with docetaxel and gemcitabine 13 , or concomitant radiotherapy 14 . Renal dysfunction may increase risk of pulmonary toxicity, as noted with bleomycin 17,18 , whilst prior smoking history may also increase risk of bleomycin related pulmonary toxicity 19,20 . The exact mechanisms by which cytotoxic agents cause lung injury have not been completely elucidated, however two main mechanisms are recognised 21 .…”

Imatinib may reduce chemotherapy-induced pneumonitis. A report on four cases from the SWENOTECA

“…But these reductions in capacity are mostly reversible during follow-up. In the majority of previous studies, both decreased VC and FVC observed during chemotherapy are usually normalized at follow-up [21][22][23][24]. However, the increased mortality as a result of respiratory diseases among chemotherapy-treated testicular cancer survivors is worrisome [1].…”

A case of bleomycin-induced lung toxicity

“…Lung toxicity occurs sporadically at doses less than 450 IU but at doses above this range the incidence rises steeply [5,6]. Smoking is another risk factor for bleomycininduced pulmonary toxicity [14]. Other suggested risk factors include dose rate, combination with other drugs, e.g.…”

Life-Threatening Pneumonitis Related to Docetaxel Chemotherapy

“…Drug interactions with other concomitant drugs or treatments may increase the risk of pulmonary toxicity, as with docetaxel and gemcitabine 13 , or concomitant radiotherapy 14 . Renal dysfunction may increase risk of pulmonary toxicity, as noted with bleomycin 17,18 , whilst prior smoking history may also increase risk of bleomycin related pulmonary toxicity 19,20 . The exact mechanisms by which cytotoxic agents cause lung injury have not been completely elucidated, however two main mechanisms are recognised 21 .…”